PFNX News and Press, Pfenex Inc. From 03/27/19

SAN DIEGO, March 27, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX), a clinical-stage development and licensing biotechnology company focused on leveraging its Pf ēnex Expression Technology® to improve protein therapies for unmet patient needs, announced today that ...

SAN DIEGO, March 26, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) a clinical-stage development and licensing biotechnology company focused on leveraging its Pf ēnex Expression Technology® to improve protein therapies for unmet patient needs, announced today that S...

The following slide deck was published by Pfenex Inc. in conjunction with this Read more ...

Pfenex Inc. (PFNX) Q4 2018 Earnings Conference Call March 11, 2019, 04:30 PM ET Company Participants Eef Schimmelpennink - President and CEO Susan Knudson - CFO Conference Call Participants Jason Butler - JMP Securities Andy Hsieh - William Blair Presentation Operato...

Pfenex (NYSEMKT: PFNX ): Q4 GAAP EPS of -$0.22. Revenue of $3.35M (-81.3% Y/Y) misses by $1.04M . Press Release More news on: Pfenex Inc., Earnings news and commentary, Healthcare stocks news, ,

We believe PF708 is on track to enter the U.S. market as early as Q4 2019, subject to FDA approval and other factors Several significant milestones across the Company’s pipeline are expected in 2019 SAN DIEGO, March 11, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PF...

Pfenex (NYSEMKT: PFNX ) is up  6%  after hours in response to successful results from an India-based Phase 3 clinical trial evaluating Pneumosil, a 10-valent pneumococcal conjugate vaccine, conducted by Serum Institute of India Private Limited. All primary and secondary endpoints...

SAN DIEGO, March 06, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) today announced that Serum Institute of India Private Limited (SIIPL), has completed a pivotal Phase 3 study for Pneumosil® a 10-valent pneumococcal conjugate vaccine, in which Serum Institute indicates all...

SAN DIEGO, March 04, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX), a clinical-stage development and licensing biotechnology company focused on leveraging its Pf ēnex Expression Technology® to improve protein therapies for unmet patient needs, today announced the a...

Pfenex ( PFNX +2.6% ) expands its agreement with Alvogen Ltd. to develop and commercialize PF708, a biosimilar to Eli Lilly's ( LLY +0.8% ) osteoporosis med FORTEO (teriparatide), to the EU, certain countries in Middle East and North Africa (MENA) and rest-of-world (ROW) territori...